Primary outcome measures
| Aspirin | No aspirin | Ticagrelor | No ticagrelor | |
| ITT analysis set# | 60 | 60 | 58 | 62 |
| Baseline | 1 | 6 | 4 | 1 |
| 1.7 (0.2–11.3) | 10 (4.5–20.8) | 6.9 (2.6–17.3) | 1.6 (0.2–10.9) | |
| 6 months | 29 | 7 | 24 | 2 |
| 48.3 (35.8–61) | 11.7 (5.6–22.8) | 41.4 (29.3–54.6) | 3.2 (0.8–12.3) | |
| PP analysis set¶ | 41 | 45 | 32 | 54 |
| 6 months | 28 | 7 | 22 | 2 |
| 68.3 (52.3–80.9) | 15.6 (7.5–29.6) | 68.8 (50.4–82.6) | 3.7 (0.9–14.0) |
Data are presented as n or % (95% CI). ITT: intention-to-treat; PP: per-protocol. #: descriptive statistics for the primary outcome of response for the comparative groups at baseline and 6 months for the ITT analysis set; ¶: response is ASPI response in the aspirin and no-aspirin columns and adenosine diphosphate response in the ticagrelor and no-ticagrelor columns.